PL1765289T3 - Kompozycje i sposoby stabilizacji preparatów adiuwantowych opartych na lipidach z użyciem glikolipidów - Google Patents

Kompozycje i sposoby stabilizacji preparatów adiuwantowych opartych na lipidach z użyciem glikolipidów

Info

Publication number
PL1765289T3
PL1765289T3 PL05756461T PL05756461T PL1765289T3 PL 1765289 T3 PL1765289 T3 PL 1765289T3 PL 05756461 T PL05756461 T PL 05756461T PL 05756461 T PL05756461 T PL 05756461T PL 1765289 T3 PL1765289 T3 PL 1765289T3
Authority
PL
Poland
Prior art keywords
glycolipids
compositions
methods
lipid based
based adjuvant
Prior art date
Application number
PL05756461T
Other languages
English (en)
Inventor
Jesper Davidsen
Ida Rosenkrands
Peter Andersen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1765289(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Publication of PL1765289T3 publication Critical patent/PL1765289T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
PL05756461T 2004-07-07 2005-07-05 Kompozycje i sposoby stabilizacji preparatów adiuwantowych opartych na lipidach z użyciem glikolipidów PL1765289T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200401070 2004-07-07
PCT/DK2005/000467 WO2006002642A2 (en) 2004-07-07 2005-07-05 Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
EP05756461A EP1765289B1 (en) 2004-07-07 2005-07-05 Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids

Publications (1)

Publication Number Publication Date
PL1765289T3 true PL1765289T3 (pl) 2009-02-27

Family

ID=34982425

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05756461T PL1765289T3 (pl) 2004-07-07 2005-07-05 Kompozycje i sposoby stabilizacji preparatów adiuwantowych opartych na lipidach z użyciem glikolipidów

Country Status (16)

Country Link
EP (1) EP1765289B1 (pl)
JP (1) JP4987704B2 (pl)
KR (1) KR101275837B1 (pl)
CN (1) CN1980638B (pl)
AT (1) ATE406874T1 (pl)
AU (1) AU2005259685B2 (pl)
BR (1) BRPI0512757B8 (pl)
CA (1) CA2572985C (pl)
DE (1) DE602005009535D1 (pl)
DK (1) DK1765289T3 (pl)
ES (1) ES2315880T3 (pl)
PL (1) PL1765289T3 (pl)
PT (1) PT1765289E (pl)
SI (1) SI1765289T1 (pl)
WO (1) WO2006002642A2 (pl)
ZA (1) ZA200701043B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2040745B1 (en) 2006-06-28 2012-12-05 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
WO2008042973A2 (en) 2006-10-03 2008-04-10 Alnylam Pharmaceuticals, Inc. Lipid containing formulations
PL2167124T3 (pl) 2007-06-29 2012-12-31 Statens Seruminstitut Zastosowanie monomikoliloglicerolu (MMG) jako adiuwantu
CN102170903B (zh) * 2008-05-02 2016-04-06 亮点医疗有限公司 用于刺激免疫反应的产品和方法
AU2010203451B2 (en) * 2009-01-08 2016-06-30 Albert Einstein College Of Medicine, Inc. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
CN102482666B (zh) * 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
PT2588133T (pt) * 2010-07-02 2018-03-05 Intervet Int Bv Vacina contra ehrlichia canis e métodos associados
WO2013004234A2 (en) 2011-07-04 2013-01-10 Statens Serum Institut Methods for producing liposomes
JP6182457B2 (ja) * 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
AU2012353463B2 (en) * 2011-12-12 2017-08-24 Kyowa Hakko Kirin Co., Ltd. Lipid nanoparticles containing combinations of cationic lipids
JP2016175841A (ja) * 2013-08-02 2016-10-06 三郎 斎藤 リポソームと、細胞障害性ｔ細胞活性を誘導するワクチン組成物
UA121200C2 (uk) * 2013-09-19 2020-04-27 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
EP3189853A4 (en) * 2014-08-04 2018-07-11 Nitto Denko Corporation Immune-induction-promoting composition including nuclear receptor ligand, and vaccine pharmaceutical composition
KR102085968B1 (ko) * 2015-07-20 2020-03-06 조에티스 서비시즈 엘엘씨 리포솜 보조제 조성물
US12064480B2 (en) 2018-04-13 2024-08-20 Glaxosmithkline Biologicals Sa Immunigenic alpha-branched trehalose-diesters
KR20230002680A (ko) * 2020-04-15 2023-01-05 스태튼스 세룸 인스티튜트 병원성 감염의 예방 또는 조기 치료 용도의 리포솜 조성물
CN114657147B (zh) * 2022-01-27 2023-12-01 安徽智飞龙科马生物制药有限公司 一种生物材料的保护剂及其应用
CN115068602B (zh) * 2022-08-22 2022-11-01 北京华诺泰生物医药科技有限公司 一种表面改性氧化铝的复合疫苗佐剂、制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108934A (en) * 1983-11-30 1992-04-28 Kabushiki Kaisha Toshiba Quantitative immunoassay utilizing liposomes
JP2714972B2 (ja) * 1988-02-02 1998-02-16 千葉製粉株式会社 リン脂質集合体用修飾剤、リン脂質小胞体用凝集防止剤、リン脂質小胞体用融合防止剤およびリン脂質膜用表面固定化剤
JPH03249561A (ja) * 1990-02-28 1991-11-07 Toshiba Corp 免疫分析試薬
JPH0482824A (ja) * 1990-07-23 1992-03-16 Nippon Oil & Fats Co Ltd リポソーム及び水中油型エマルション
JPH0616688A (ja) * 1992-06-30 1994-01-25 Nippon Oil & Fats Co Ltd 脂肪酸糖エステル
JP3329554B2 (ja) * 1993-03-10 2002-09-30 千葉製粉株式会社 乾燥小胞体
JP3884488B2 (ja) * 1993-03-10 2007-02-21 千葉製粉株式会社 オリゴ糖脂質
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
JPH0925287A (ja) * 1995-07-13 1997-01-28 Eisai Co Ltd 合成脂質
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
GB9808268D0 (en) * 1998-04-17 1998-06-17 Imp College Innovations Ltd Compound
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
EP1404298A2 (en) * 2001-06-25 2004-04-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparation of vesicles loaded with biological material and different uses thereof

Also Published As

Publication number Publication date
CA2572985C (en) 2014-04-22
ES2315880T3 (es) 2009-04-01
DK1765289T3 (da) 2008-12-15
EP1765289A2 (en) 2007-03-28
JP2008505131A (ja) 2008-02-21
BRPI0512757B1 (pt) 2021-04-06
KR101275837B1 (ko) 2013-06-18
CA2572985A1 (en) 2006-01-12
WO2006002642A3 (en) 2006-05-18
CN1980638A (zh) 2007-06-13
EP1765289B1 (en) 2008-09-03
BRPI0512757A (pt) 2008-04-08
DE602005009535D1 (de) 2008-10-16
PT1765289E (pt) 2008-12-05
AU2005259685B2 (en) 2010-04-08
BRPI0512757B8 (pt) 2021-05-25
SI1765289T1 (sl) 2009-02-28
JP4987704B2 (ja) 2012-07-25
AU2005259685A1 (en) 2006-01-12
ATE406874T1 (de) 2008-09-15
WO2006002642A2 (en) 2006-01-12
ZA200701043B (en) 2007-12-27
KR20070051847A (ko) 2007-05-18
CN1980638B (zh) 2011-10-12

Similar Documents

Publication Publication Date Title
ZA200701043B (en) Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
Levast et al. Vaccine potentiation by combination adjuvants
WO2021154812A8 (en) Coronavirus vaccine formulations
EP4056198A3 (en) Outer membrane vesicles
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
ZA202101465B (en) Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
RU2013114392A (ru) Маленькие липосомы для доставки кодирующей иммуноген рнк
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
WO2005016239A3 (en) Molecules enhancing dermal delivery of influenza vaccines
CA2448208A1 (en) Influenza vaccine composition
AU2002254901A1 (en) Influenza vaccine formulations for intradermal delivery
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
MY126588A (en) Intranasal influenza virus vaccine
MX2009008928A (es) Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
WO2007068907A3 (en) Vaccine compositions comprising a saponin adjuvant
GB2386072A (en) Novel vaccine
WO2011027257A3 (en) Pcsk9 vaccine
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
EE05633B1 (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
MXPA05013929A (es) Membranas virales reconstruidas funcionalmente que contienen un adyuvante.
WO2008093772A1 (ja) 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
ATE419873T1 (de) Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
CN119968210A (zh) 用于预防或治疗结核病的rna
WO2023102448A3 (en) Coronavirus vaccine formulations